1411TiP GFPC 06-2018: A multicenter non-randomized phase II study evaluating platinum-pemetrexed-atezolizumab (+/-bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after targeted therapies